Published on
05:45 GMT
Psychedelics Space Enters New Era as AbbVie Dives In
Replete with fast-acting, even curative potential, psychedelic therapeutics have long piqued the interest of Big Pharma. Johnson & Johnson’s ketamine derivative Spravato hit the U.S. market in 2019 for depression, and in 2023, Japan-based Otsuka …
Source:
BioSpace
-
Pending
20250915212374.png)
